Starting
Initialising…
0%
ERBB3
Final classification
VUS
ERBB3 c.1008_1010inv · p.Gly337Gln
ERBB3

NM_001982.3:c.1008_1010delTGGinsCCA (p.Gly337Gln) in ERBB3 was assessed using the generic ACMG/AMP 2015 framework (PMID:25741868).

Gene
ERBB3
Transcript
NM_001982.3
HGVS · transcript:coding
NM_001982.3:c.1008_1010inv
Consequence
N/A
GRCh38
chr12:56088767 TGG>CCA
GRCh37
chr12:56482551 TGG>CCA
Basis gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting; combination = 1 supporting, which maps to VUS.
gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting; combination = 1 supporting, which maps to VUS.
Classification rationale
PM2 VUS
ERBB3 c.1008_1010inv

NM_001982.3:c.1008_1010delTGGinsCCA (p.Gly337Gln) in ERBB3 was assessed using the generic ACMG/AMP 2015 framework (PMID:25741868).1 PVS1 is not applicable: the variant produces a single missense substitution, not a null variant in a gene where loss of function is a known disease mechanism.2 The variant is absent from gnomAD v2.1, v4.1, and gnomAD-Canada (allele frequency 0.0). PM2 is met at supporting strength.3 The variant is absent from ClinVar with no functional data, no de novo observations, no case-control studies, no segregation data, and no in silico scores applicable. All other criteria are not met, not applicable, or not assessed.4 With only PM2_supporting met, the variant is classified as a Variant of Uncertain Significance (VUS) under generic ACMG/AMP 2015 combination rules.5

PM2 VUS
1 generic_acmg_combination_rules
5 generic_acmg_combination_rules
Gene diagram · NM_001982.3 · variants mapped to exon structure
ERBB3 NM_001982.3
Fetching transcript structure from UCSC…
Applied criteria · 1 met · select any tile
Met
Not met
Not assessed
N/A
Strength very strong supporting
Pathogenic evidence
PVS
PS
PM
PP
Benign evidence
BA
BS
BP
Rationale
Select a criterion.
Sources
Evidence used
    Gaps remaining
      Rule
      Research & evidence
      Population frequency
      gnomAD v4.1 screenshot
      gnomAD v4.1
      gnomAD v2.1 screenshot
      gnomAD v2.1
      v4.1
      Absent from gnomAD v4.1.
      v2.1
      Absent from gnomAD v2.1.
      🇨🇦 CA
      Absent from gnomAD-Canada v1.0.
      Allele frequency by ancestry
      three datasets · side by side
      gnomAD v4.1
      Absent · 0 / ?
      0 hom
      Not observed in any ancestry group.
      gnomAD v2.1
      Absent · 0 / ?
      0 hom
      Not observed in any ancestry group.
      gnomAD Canada 🇨🇦
      Absent · 0 / ?
      0 hom
      Not observed in any ancestry group.
      ClinVar screenshot
      ClinVar
      This variant is absent from ClinVar.
      SpliceAI screenshot
      In silico
      SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01).
      Functional / OncoKB screenshot
      Functional Unknown Oncogenic Effect
      OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types.
      OncoKB ↗
      COSMIC screenshot
      COSMIC
      Cancer hotspots screenshot
      Cancer hotspots
      Somatic evidence Hotspot
      COSMIC
      This variant lies in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
      Hotspots
      This variant lies in a statistically significant hotspot.
      Sources & reference links
      8Sources
      ClinVar
      gnomAD v2.1
      gnomAD v4.1
      gnomAD-Canada
      SpliceAI
      OncoKB
      COSMIC
      Cancer hotspots